- Home
- DAWN vs PEO Comparison
DAWN vs PEO Comparison
Compare DAWN & PEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DAWN
- PEO
- Stock Information
- Founded
- DAWN 2018
- PEO 1929
- Country
- DAWN United States
- PEO United States
- Employees
- DAWN N/A
- PEO N/A
- Industry
- DAWN Biotechnology: Pharmaceutical Preparations
- PEO Finance/Investors Services
- Sector
- DAWN Health Care
- PEO Finance
- Exchange
- DAWN Nasdaq
- PEO Nasdaq
- Market Cap
- DAWN 624.8M
- PEO 569.6M
- IPO Year
- DAWN 2021
- PEO N/A
- Fundamental
- Price
- DAWN $7.15
- PEO $21.61
- Analyst Decision
- DAWN Strong Buy
- PEO
- Analyst Count
- DAWN 7
- PEO 0
- Target Price
- DAWN $27.86
- PEO N/A
- AVG Volume (30 Days)
- DAWN 1.1M
- PEO 35.4K
- Earning Date
- DAWN 10-29-2025
- PEO 01-01-0001
- Dividend Yield
- DAWN N/A
- PEO 5.93%
- EPS Growth
- DAWN N/A
- PEO N/A
- EPS
- DAWN N/A
- PEO N/A
- Revenue
- DAWN $187,638,000.00
- PEO N/A
- Revenue This Year
- DAWN $12.56
- PEO N/A
- Revenue Next Year
- DAWN $48.02
- PEO N/A
- P/E Ratio
- DAWN N/A
- PEO N/A
- Revenue Growth
- DAWN 2190.50
- PEO N/A
- 52 Week Low
- DAWN $5.64
- PEO $19.22
- 52 Week High
- DAWN $16.76
- PEO $23.80
- Technical
- Relative Strength Index (RSI)
- DAWN 51.15
- PEO 53.94
- Support Level
- DAWN $7.03
- PEO $21.30
- Resistance Level
- DAWN $7.58
- PEO $21.78
- Average True Range (ATR)
- DAWN 0.27
- PEO 0.25
- MACD
- DAWN -0.04
- PEO -0.00
- Stochastic Oscillator
- DAWN 29.55
- PEO 40.63
About DAWN Day One Biopharmaceuticals Inc.
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, and kinase inhibitor.
About PEO Adams Natural Resources Fund Inc.
Adams Natural Resources Fund Inc is a non-diversified U.S. equity fund that invests in liquid energy and other natural resources stocks. The Fund's investment objectives are preservation of capital, reasonable income, and opportunity for capital gain. A majority of its assets are invested in petroleum or natural resources industries or industries connected to them. It has broad flexibility to invest in stocks of varying capitalizations and predominantly invests in stocks found in the S&P 500 Energy and S&P 500 Materials sectors.